{"filings":[{"id":2271236,"accession_number":"0001295947-26-000049","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-08-14T20:03:51+00:00","items":["5.02"],"status":"ready","headline":"Prestige Consumer Healthcare SVP Operations Jeffrey Zerillo to retire Aug 14, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Zerillo, Senior Vice President, Operations, notified company of retirement on Aug 10, 2026.","Retirement effective Aug 14, 2026; he will leave all positions held with the company.","No successor or interim replacement named in the filing.","Company ticker PBH; filing made under Item 5.02."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2087640,"accession_number":"0001295947-26-000040","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-08-06T10:04:34+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q1 revenue $265.7M (+6.5%), adj. EPS $0.98; raises FY outlook to $1.29-1.315B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $265.7M (+6.5% YoY); organic sales growth 3.2% exceeded expectations.","GAAP diluted EPS $0.61; adjusted diluted EPS $0.98 vs $0.95 prior year.","Closed Breathe Right acquisition (June) and LaCorium (July); added $6M revenue in Q1.","Raised FY2027 outlook: revenue $1,290-$1,315M, adj. EPS $4.55-$4.65 (from $4.42-$4.51).","Issued $400M 6.25% senior notes due 2034, extending nearest maturity to 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1664196,"accession_number":"0001104659-26-083872","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-07-15T20:03:15+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare subsidiary issues $400M 6.250% senior notes due 2034","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M aggregate principal of 6.250% senior notes due July 15, 2034 issued by Prestige Brands, Inc.","Interest payable semi-annually on Jan 15 and Jul 15, starting Jan 15, 2027.","Notes are senior unsecured obligations, guaranteed by Prestige Consumer Healthcare and certain subsidiaries.","Redemption: on/after Jul 15, 2029 at specified prices; prior to that at make-whole premium; up to 40% with equity offering proceeds.","Change of control triggers offer at 101% of principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1554836,"accession_number":"0001295947-26-000032","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K/A","filed_at":"2026-07-09T20:43:31+00:00","items":["9.01"],"status":"ready","headline":"Prestige files 8-K/A with OTC Wellness Business Q1 2026 financials; net income $12.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OTC Wellness Business net sales $51.7M for Q1 2026, up 2.4% YoY from $50.5M.","Net income $12.6M, down 14.4% from $14.8M in Q1 2025; operating income $12.6M.","Gross sales $64.1M; sales allowances, returns & discounts $12.4M (19.4% of gross).","Advertising & promotion expense $12.6M, up 24.6% YoY from $10.2M.","Filing corrects prior 8-K/A by removing inadvertently included audit report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1453957,"accession_number":"0001295947-26-000029","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-07-06T12:05:15+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Prestige closes LaCorium acquisition for ~$150M, prices $400M notes at 6.25% due 2034","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of LaCorium Health for ~$150M cash; LaCorium has ~$40M annual revenue, expected ~$12M EBITDA post-synergies.","Priced $400M senior notes at 6.25% due 2034; proceeds to redeem existing 5.125% notes due 2028.","Borrowed $95M additional term loans under existing credit agreement to finance part of acquisition.","Q1 FY2027 earnings results to be released on August 6, 2026, with conference call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1341961,"accession_number":"0001295947-26-000025","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K/A","filed_at":"2026-06-30T10:01:12+00:00","items":["9.01"],"status":"ready","headline":"Acquired OTC Wellness Business Q1 net sales $51.7M, net income $12.6M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net sales of $51.7M for Q1 2026, up 2.4% from $50.5M in Q1 2025.","Net income of $12.6M, down 14.4% from $14.8M in prior-year quarter.","Intangible assets net of $328.3M and goodwill of $151.5M as of March 31, 2026.","Business includes brands Breathe Right, Dimetapp, Anbesol, Alavert, Primatene, and others.","Pro forma financials for Prestige Consumer Healthcare also filed as part of the acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1065396,"accession_number":"0001104659-26-074259","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-06-16T10:15:52+00:00","items":["1.01","2.01","2.03","8.01","9.01"],"status":"ready","headline":"Prestige closes $1.045B acquisition of Breathe Right brand from Foundation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $1.045B cash; net of $150M tax benefits, effective cost ~$900M.","Financed via new Term Loan B of $1.045B (Term SOFR + 2.00%) and cash on hand.","ABL facility amended and upsized to $225M with 5-year maturity from closing.","Breathe Right becomes Prestige's largest brand, entering a new nasal strip category.","LaCorium acquisition expected Q2 FY27; up to $95M additional term loans available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69282,"accession_number":"0001295947-26-000013","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-05-13T20:35:45+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer reports FY26 adj EPS $4.38; acquires LaCorium Health for $150M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FY26 revenue $1,088.7M (-4.3% YoY); adjusted diluted EPS $4.38 vs $4.52 prior year.","Q4 revenue $281.6M (-5% YoY); adjusted diluted EPS $1.23 vs $1.32.","Acquiring LaCorium Health (Australian therapeutic skincare) for ~$150M cash; expected close Q2 FY27.","LaCorium TTM revenue ~$40M; expected ~$12M EBITDA with synergies.","FY27 outlook: organic revenue growth 1-3%, adj EPS $4.42-$4.51, FCF $250M+."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102418,"accession_number":"0001104659-26-032332","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare to acquire Breathe Right brand portfolio for $1.045B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition includes Breathe Right, Dimetapp, Anbesol brands; trailing revenue $200M, EBITDA $95M.","Purchase price $1.045B cash; net ~$900M after $150M anticipated tax benefits.","Implied multiple of 11.0x EBITDA (9.5x net of tax benefits); accretive to gross/EBITDA margins and EPS.","Expected pro-forma net leverage ~4.0x at closing; target below 3.0x by fiscal 2028.","Transaction expected to close in first half fiscal 2027, subject to HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102417,"accession_number":"0001295947-26-000006","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.","Narrowed FY2026 revenue outlook to ~$1.1B from $1.1-1.115B; adjusted EPS ~$4.54.","Repurchased ~0.8M shares in Q3 for $45.8M; YTD repurchases ~2.3M shares at $155.6M.","Closed acquisition of eye care supplier Pillar5 Pharma in December 2025.","Clear Eyes supply constraints continue; management expects supply improvements in coming quarters."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":807088000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118691,"accession_number":"0001295947-25-000037","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.","Raises FY2026 adjusted diluted EPS outlook to $4.54-$4.58 (high end of prior range).","Repurchased ~1.1M shares in Q2 for $75M; cumulative 1.6M shares in H1 for $109.8M.","Clear Eyes supply constraints drove OTC revenue decline; expects improvement in H2 via capacity rebuild.","Free cash flow guidance reaffirmed at $245M+; covenant leverage 2.4x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":523644000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135202,"accession_number":"0001295947-25-000027","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).","Clear Eyes supply constraints drove North American OTC revenue down to $212.6M.","Acquiring Pillar5 Pharma for CAD 150M cash; expected to close Q3 FY2026.","FY2026 outlook cut: revenue now $1.10-1.115B, EPS $4.50-4.58 (from $4.70-4.82).","Net debt ~$0.9B; leverage 2.4x; free cash flow guidance unchanged at $245M+."],"consensus_eps_estimate":1.4039,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":249530000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152177,"accession_number":"0001295947-25-000014","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q4 revenue $296.5M, adj EPS $1.32; FY25 adj EPS $4.52; FY26 outlook $4.70-4.82","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $296.5M (+7.0% YoY, organic +7.9%); diluted EPS $1.00 GAAP, adjusted $1.32 (vs $1.02 prior year).","FY2025 revenue $1,137.8M (+1.1%); diluted EPS $4.29 GAAP, adjusted $4.52 (+7.4% vs $4.21 prior year).","Free cash flow $243.3M in FY2025 (+1.6% YoY); leverage ratio reduced to 2.4x at year-end.","Initial FY2026 outlook: organic revenue growth ~1-2%, diluted EPS $4.70-4.82, free cash flow $245M or more.","Management guides mid-to-high single-digit EPS growth despite ~$15M tariff headwind."],"consensus_eps_estimate":1.1557,"consensus_eps_actual":4.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1137762000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171008,"accession_number":"0001295947-25-000007","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 FY2025 EPS $1.22 (+15% YoY); raises FY25 adjusted EPS outlook to ~$4.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $290.3M (+2.7% YoY); record quarterly sales and EPS.","Diluted EPS $1.22 vs $1.06 prior year; net income $61.0M vs $53.0M.","Raises FY25 adjusted EPS outlook to ~$4.50 from $4.40-$4.46; FCF ≥$240M reaffirmed.","International OTC segment grew 11.3% (8.3% ex-FX); North American OTC +1.0%.","Leverage reduced to 2.5x; repurchased 0.6M shares for ~$40.2M YTD."],"consensus_eps_estimate":0.98,"consensus_eps_actual":3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":841244000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171007,"accession_number":"0001104659-25-001076","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare expands CFO Christine Sacco's role to include COO, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine Sacco, CFO since 2016, appointed COO/CFO effective Jan 6, 2025; will oversee supply chain.","New compensation: base salary $700k, target cash incentive 75% of salary, LTIP target $1.575M.","Received a $1.575M time-based RSU retention award cliff vesting in 4 years.","No family relationships or arrangements with other persons for her appointment disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187983,"accession_number":"0001295947-24-000030","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.","North American OTC down 1.9% to $239.8M; International OTC up 5.0% to $44.0M driven by Hydralyte.","Free cash flow $67.8M in Q2; net cash from operations $69.8M, up 11.7% YoY.","Repurchased ~0.2M shares for $12M in Q2; reduced debt by $75M YTD; leverage ratio 2.7x.","Reaffirmed FY2025 outlook: revenue $1,125-1,140M, adj. diluted EPS $4.40-4.46, free cash flow $240M+."],"consensus_eps_estimate":1.0102,"consensus_eps_actual":2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":550927000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204485,"accession_number":"0001295947-24-000023","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.","Cash from operations $54.8M (+13.9% YoY); reduced debt $35M and repurchased $26M in shares.","North American OTC revenue $232.3M (-5.6%); International OTC $34.8M (+5.0% driven by Hydralyte).","FY2025 guidance reaffirmed: revenue $1.125-$1.140B, adjusted EPS $4.40-$4.46, FCF $240M+.","CEO cited earlier supply of Clear Eyes products as primary driver of Q1 beat over expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":267142000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221286,"accession_number":"0001295947-24-000015","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Q4 revenue down 2.9%; adj. EPS $1.02; $300M buyback; FY2025 EPS guidance $4.40-$4.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $277.0M (-2.9% ex-FX); non-GAAP adj. diluted EPS $1.02 vs $1.07 prior year.","Full-year FY2024 revenue $1,125.4M (flat); GAAP diluted EPS $4.17; non-GAAP diluted EPS $4.21.","Leverage ratio improved to 2.8x, below 3x target; net debt ~$1.1B.","Board authorized new $300M share repurchase program; timing subject to market conditions.","Initial FY2025 guidance: organic revenue growth ~1%, diluted EPS $4.40-$4.46, free cash flow $240M+."],"consensus_eps_estimate":null,"consensus_eps_actual":4.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1125357000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221285,"accession_number":"0001104659-24-058841","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prestige Consumer Healthcare elects John F. Kelly, former Pfizer VP, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John F. Kelly, former Vice President Quality Operations and EHS at Pfizer, elected to PBH Board on May 7, 2024.","Appointed to Compensation and Talent Management and Nominating and Corporate Governance Committees.","Kelly retired in 2022 after 40-year career at Pfizer, including leading global quality and EHS functions.","No related party transactions or arrangements in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240842,"accession_number":"0001295947-24-000006","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q3 revenue $282.7M (+2.6% YoY), raises FY EPS outlook to ~$4.33","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $1.06 in Q3, up 2.2% vs $1.04 prior year; net income $53.0M.","North America OTC revenue $236.6M flat; International OTC rose to $46.2M (+19.7%) driven by Hydralyte.","Net debt ~$1.1B; leverage ratio improved to 2.9x; free cash flow $69.5M in Q3.","Full-year revenue guidance reaffirmed $1,135-1,140M; diluted EPS raised from $4.27-4.32 to ~$4.33.","Completed $25M share repurchase in Q1; no new buyback authorization announced."],"consensus_eps_estimate":null,"consensus_eps_actual":3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":848366000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258345,"accession_number":"0001104659-23-125696","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare amends ABL facility: $41.5M commitment increase, maturity extended to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit commitments increased by $41.5M (exhibit shows $41.5M, not $25M cited in filing summary).","Maturity extended to five years from Dec 8, 2023 (Dec 8, 2028), subject to springing maturity.","Deutsche Bank NY Branch exited as lender; a new lender joined with assignments and reallocations.","Amendment provides increased flexibility on restricted payments, debt incurrence, and borrowing base.","Borrower paid amendment fees: 0.10% of outstanding commitments plus 0.15% of new money commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258344,"accession_number":"0001295947-23-000032","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare Q2 rev $286.3M, EPS $1.07, leverage down to 3.0x","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 FY2024 revenue $286.3M, slightly below prior-year record of $289.3M but ahead of internal outlook.","Diluted EPS $1.07 vs $1.02 YoY, up 5.4%; net income $53.6M vs $51.0M.","North American OTC revenue fell 3% to $244.4M; International OTC rose ~12.6% to $41.9M.","Non-GAAP free cash flow $59.5M, up from $55.2M; covenant leverage ratio improved to 3.0x.","FY2024 outlook reaffirmed: rev $1,135-1,140M, diluted EPS $4.27-4.32, FCF $240M+."],"consensus_eps_estimate":null,"consensus_eps_actual":2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":565625000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275648,"accession_number":"0001295947-23-000024","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare Q1 revenue $279.3M (+0.8% YoY); reaffirms FY2024 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $279.3M, up 0.8% YoY (1.8% ex-FX); net income $53.3M, diluted EPS $1.06 vs $1.09 prior year.","North American OTC revenue $246.1M (+1.5%); International OTC $33.2M, down from $34.5M on $1.9M FX headwind.","Completed $25M share repurchase (~0.4M shares); net debt ~$1.3B, leverage ratio 3.2x.","Reaffirmed FY2024 outlook: revenue $1,135-1,140M, diluted EPS $4.27-4.32, free cash flow $240M+.","Free cash flow $46.6M in Q1 vs $57.2M prior year, impacted by working capital timing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":279309000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293187,"accession_number":"0001295947-23-000014","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare reports record FY23 revenue $1.1277B; guides FY24 EPS $4.27-$4.32","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $285.9M (+7.1% YoY, +8.0% organic); adjusted EPS $1.07 vs $0.91 prior year.","Full year FY23 revenue $1.1277B (record); net loss $82.3M on impairments; adjusted EPS $4.21.","FY24 guidance: revenue $1.135-$1.140B, diluted EPS $4.27-$4.32, free cash flow $240M+.","Board authorized $25M share repurchase through May 2024.","Covenant leverage ratio 3.3x; new long-term target below 3.0x."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1127725000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313824,"accession_number":"0001295947-23-000006","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 revenue $275.5M (+0.4%), EPS $1.04 (+5.1%); guides FY23 EPS ~$4.18","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $275.5M (+0.4% YoY; +1.8% ex-currency); diluted EPS $1.04 (+5.1% vs $0.99).","International OTC revenue $38.6M (+15% YoY); North American OTC $236.9M (-1.7%).","Leverage ratio reduced to 3.5x, lowest in over 10 years; net debt ~$1.4B.","FY2023 guidance: revenue $1,120-1,122M, diluted EPS ~$4.18, free cash flow ~$220M.","Nine-month revenue $841.9M (+2.7% YoY); net income $158.2M vs $153.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":841856000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332282,"accession_number":"0001295947-22-000030","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q2 revenue $289.3M (+4.7% YoY), EPS $1.02; reaffirms FY2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $289.3M (+4.7% YoY, +5.5% ex-currency); diluted EPS $1.02, ahead of expectations.","International OTC segment revenue $37.2M (+51.9% YoY) driven by Hydralyte demand.","Reduced debt by $35M; leverage ratio 3.7x; completed $50M share repurchase program.","Reaffirms FY2023 outlook: revenue $1.12-1.13B, diluted EPS $4.18-4.23, FCF $260M+."],"consensus_eps_estimate":null,"consensus_eps_actual":2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":566332000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349746,"accession_number":"0001295947-22-000020","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q1 FY2023 revenue $277.1M, EPS $1.09, reaffirms full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $277.1M, +2.9% YoY; organic revenue (ex-Akorn, FX) declined 1.2%.","Diluted EPS $1.09 vs $1.14 prior year, but ahead of internal expectations.","Net cash from operations $58.2M; Non-GAAP free cash flow $57.2M.","Reaffirmed FY2023 guidance: revenue $1.12-1.13B, EPS $4.18-4.23, FCF >=$260M.","North American OTC flat at $242.5M; International OTC record $34.5M (+28.9%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":277059000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366795,"accession_number":"0001295947-22-000012","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare reports record FY2022 revenue $1.087B, adj. EPS $4.06, authorizes $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $266.9M (+12.3% YoY); full-year revenue $1,086.8M (+15.2% YoY).","Full-year GAAP diluted EPS $4.04; adjusted diluted EPS $4.06, up 25.3%.","Record non-GAAP free cash flow $253.7M; operating cash flow $259.9M.","Initial FY2023 outlook: revenue ~$1.125B, diluted EPS $4.18-$4.23, FCF $260M+.","Board authorized $50M share repurchase program through May 2023; net leverage 3.8x."],"consensus_eps_estimate":null,"consensus_eps_actual":4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1086812000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386183,"accession_number":"0001295947-22-000007","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 revenue $274.5M (+14.9% YoY), EPS $0.99 (+22.2%); raises FY22 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $274.5M, up 14.9% YoY; organic growth 8.8% excluding currency and Akorn acquisition.","Diluted EPS $0.99, up 22.2% YoY; FY22 adjusted diluted EPS guidance raised to $4.00-$4.04.","Non-GAAP free cash flow $64.1M in Q3 vs $43.5M prior year; FY22 free cash flow guidance raised to $250M+.","North America OTC segment $240.9M (+14.4%); International OTC $33.6M (+19.3% record).","Paid down $70M debt in Q3; net debt ~$1.5B, covenant leverage ratio 3.9x."],"consensus_eps_estimate":null,"consensus_eps_actual":3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":819876000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404106,"accession_number":"0001295947-21-000036","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q2 fiscal 2022 revenue record $276.2M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $276.2M (+16.3% YoY); organic growth 10.5% ex-Akorn and FX.","Adjusted diluted EPS $1.02, up 30.8% YoY; GAAP diluted EPS $0.89.","Raising FY2022 outlook: revenue $1.05-$1.06B (prior $1.045B+); adj. EPS $3.93-$3.98 (prior $3.90+).","North American OTC segment $251.7M (+16.2%); International OTC $24.5M (+17.5%).","Adjusted free cash flow $61.9M in Q2; net debt ~$1.6B with leverage 4.1x."],"consensus_eps_estimate":null,"consensus_eps_actual":2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":545406000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423079,"accession_number":"0001295947-21-000027","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare Q1 revenue $269.2M (+17.3%), EPS $1.14 (+32.5%); raises FY22 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $269.2M, up 17.3% YoY; diluted EPS $1.14, up 32.5% vs prior year.","North American OTC revenue $242.4M; International OTC $26.8M, up 43% from $18.7M.","Raising FY22 guidance: revenue ~$1.045B+ (prev. $957-962M), adj. EPS $3.90+ (prev. $3.58+).","TheraTears acquisition closed July 1, expected to add ~$40M revenue and $0.07 EPS to FY22.","Net cash from ops $69.3M, free cash flow $67.8M; net debt ~$1.4B; refinanced term loan to 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":269181000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423078,"accession_number":"0001104659-21-088218","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2021-07-01T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Prestige completes $230M acquisition of TheraTears from Akorn, refinances term loan.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired TheraTears and other OTC brands from Akorn Operating Company for $230M cash, closed July 1, 2021.","Deal expected to add ~$60M annual revenue, ~$0.10 EPS, ~$13M operating cash flow.","Expected annual EBITDA ~$20M, tax benefits ~$30M; transaction valued at <10x pro-forma EBITDA.","Financed via cash, ABL revolver, and new $600M Term B-5 Loans (LIBOR+2%, floor 0.5%, maturity 2028).","Announced Q1 fiscal 2022 earnings release scheduled for August 5, 2021, conference call at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}